Literature DB >> 17893983

Drug-induced lupus.

Andrea T Borchers1, Carl L Keen, M Eric Gershwin.   

Abstract

Drug-induced lupus (DIL) is a rare adverse reaction to a large variety of drugs with features resembling those of idiopathic systemic lupus erythematosus (SLE). It usually develops only after months and, quite commonly, years of treatment with the offending agent, although latencies of days or weeks have been described in some instances. There are some indications that the risk of DIL can increase with higher daily and cumulative doses and with longer duration of therapy. There are no definitive and commonly accepted diagnostic criteria for DIL, but the following guidelines have been proposed: (a) sufficient and continuing exposure to a specific drug, (b) at least one symptom compatible with SLE, (c) no history suggestive of SLE before starting the drug, and (d) resolution of symptoms within weeks (sometimes months) after discontinuation of the putative offending agent. In addition, it is frequently suggested that the presence of ANA is required for the diagnosis of DIL. However, negative ANA test results should not automatically preclude such a diagnosis, particularly if a patient has other autoantibodies associated with SLE/DIL.

Entities:  

Mesh:

Year:  2007        PMID: 17893983     DOI: 10.1196/annals.1422.019

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  39 in total

Review 1.  Drug-induced lupus anticoagulants and antiphospholipid antibodies.

Authors:  Jeffrey S Dlott; Robert A S Roubey
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

Review 2.  Drug-induced lupus erythematosus: incidence, management and prevention.

Authors:  Christopher Chang; M Eric Gershwin
Journal:  Drug Saf       Date:  2011-05-01       Impact factor: 5.606

3.  Lupus: an overview of the disease and management options.

Authors:  William Maidhof; Olga Hilas
Journal:  P T       Date:  2012-04

4.  Analytical variability in the determination of anti-double-stranded DNA antibodies: the strong need of a better definition of the old and new tests.

Authors:  Maria Infantino; M Manfredi; M Merone; V Grossi; M Benucci; F Li Gobbi; F Bandinelli; A Damiani; P Soda
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

5.  Brief Report: Drugs Implicated in Systemic Autoimmunity Modulate Neutrophil Extracellular Trap Formation.

Authors:  Jorge A Irizarry-Caro; Carmelo Carmona-Rivera; Daniella M Schwartz; Sami S Khaznadar; Mariana J Kaplan; Peter C Grayson
Journal:  Arthritis Rheumatol       Date:  2018-01-23       Impact factor: 10.995

6.  Infliximab-Induced Lupus: A Case Report.

Authors:  Vítor Magno Pereira; Carla Andrade; Ricardo Figueira; Goreti Faria; Luís Jasmins
Journal:  GE Port J Gastroenterol       Date:  2016-11-19

Review 7.  Solving the genetic puzzle of systemic lupus erythematosus.

Authors:  Wanling Yang; Yu Lung Lau
Journal:  Pediatr Nephrol       Date:  2014-09-20       Impact factor: 3.714

8.  Lupus attributable to anti-TNF therapy and revealed by interstitial granulomatous dermatitis.

Authors:  M Guerin; B Haettich; C Bara; L Artru; B Prophette; P Célérier; H Maillard
Journal:  Rheumatol Int       Date:  2011-07-29       Impact factor: 2.631

9.  Arthritis and benznidazole: more closely related than we thought.

Authors:  E Aldasoro; M J Pinazo; I Oliveira; J Munoz; E Posada; A Requena-Méndez; N Serret; J Gascon
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

Review 10.  Primary biliary cirrhosis.

Authors:  Simon Hohenester; Ronald P J Oude-Elferink; Ulrich Beuers
Journal:  Semin Immunopathol       Date:  2009-07-15       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.